Irisin Expression & Gene Polymorphism With Peripartum Cardiomyopathy.

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04927715
Study type	Observational
Source	Sohag University
Contact	Ali mo Altaher, lecturer
Phone	01003376529
Email	dr.ali.altaher30@gmail.com
Status	Recruiting
Phase
Start date	February 20, 2021
Completion date	February 28, 2022

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04144660` - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
	Withdrawn	`NCT04143997` - Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery
	Completed	`NCT00998556` - Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy	Phase 2
	Completed	`NCT03081949` - Peripartum Cardiomyopathy in Nigeria Registry	Phase 4
	Recruiting	`NCT03364140` - A Registry of Peripartum Cardiomyopathy in Turkey	N/A
	Completed	`NCT04049136` - NT-proBNP Levels and Obesity in Pregnancy
	Recruiting	`NCT04234659` - PPCM Observational Study (Peripartum Cardiomyopathy)
	Withdrawn	`NCT02590601` - Bromocriptine in the Treatment of Peripartum Cardiomyopathy	Phase 3
	Completed	`NCT03907267` - Taurine in Peripartum Cardiomyopathy	Phase 2/Phase 3
	Recruiting	`NCT05878041` - Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.